Lymphoid tumours and breast cancer in ataxia telangiectasia; substantial protective effect of residual ATM kinase activity against childhood tumours by Reiman, A et al.
Lymphoid tumours and breast cancer in ataxia telangiectasia;
substantial protective effect of residual ATM kinase activity
against childhood tumours
A Reiman
1, V Srinivasan
1, G Barone
1, JI Last
1, LL Wootton
1, EG Davies
2, MM Verhagen
3, MA Willemsen
3,
CM Weemaes
4, PJ Byrd
1, L Izatt
5, DF Easton
6, DJ Thompson
6 and AM Taylor*,1
1School of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Edgbaston, Birmingham, B15 2TT, UK;
2Department of Immunology, Great Ormond Street Hospital & Institute of Child Health, Guilford Street, London WC1N 3JH, UK;
3Department of
Paediatric Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands;
4Department of Paediatrics, Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands;
5Clinical Genetics Department, Guy’s and St Thomas’ NHS Foundation Trust, 7th floor Borough
Wing, Great Maze Pond, London SE1 9RT, UK;
6Cancer Research UK Genetic Epidemiology Unit, Department of Public Health and Primary Care,
University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK
BACKGROUND:Immunodeficiency in ataxia telangiectasia (A-T) is less severe in patients expressing some mutant or normal ATM kinase
activity. We, therefore, determined whether expression of residual ATM kinase activity also protected against tumour development
in A-T.
METHODS: From a total of 296 consecutive genetically confirmed A-T patients from the British Isles and the Netherlands, we identified
66 patients who developed a malignant tumour; 47 lymphoid tumours and 19 non-lymphoid tumours were diagnosed. We
determined their ATM mutations, and whether cells from these patients expressed any ATM with residual ATM kinase activity.
RESULTS: In childhood, total absence of ATM kinase activity was associated, almost exclusively, with development of lymphoid tumours.
There was an overwhelming preponderance of tumours in patients o16 years without kinase activity compared with those with
some residual activity, consistent with a substantial protective effect of residual ATM kinase activity against tumour development in
childhood. In addition, the presence of eight breast cancers in A-T patients, a 30-fold increased risk, establishes breast cancer as part
of the A-T phenotype.
CONCLUSION: Overall, a spectrum of tumour types is associated with A-T, consistent with involvement of ATM in different
mechanisms of tumour formation. Tumour type was influenced by ATM allelic heterogeneity, residual ATM kinase activity and age.
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Ataxia-telangiectasia (A-T) is a rare autosomal recessive neuro-
logical disorder, typically diagnosed in early childhood and
characterised by progressive cerebellar degeneration and oculocuta-
neous telangiectasia. Almost all cases of A-T are caused by
homozygous or (more commonly) compound heterozygous muta-
tions in the ATM gene (MIM 607585) (Savitsky et al, 1995; Taylor and
Byrd, 2005). Ataxia-telangiectasia patients show a predisposition to
the development of different types of lymphoid tumours as children
or as young adults and, less frequently, they may also develop brain
and other tumours (Spector et al, 1982; Morrell et al, 1986; Taylor
et al, 1996). The spectrum of leukaemias in children with A-T is
different to that in the general population in which infant and
childhood leukaemias are mostly pre-B and B-precursor ALL,
involving a stage before V(D)J recombination. About half of them
involve Bcr-Abl, Tel-AML, MLL and other rearrangements (Greaves
and Wiemels, 2003). There appears to be no role of ATM in
protecting against B-precursor ALL, as there is no observed increase
in these tumours in A-T patients. The proposed role of ATM in V(D)J
recombination (Bredemeyer et al, 2006, 2008; Huang et al, 2007;
Vacchio et al, 2007; Hewitt et al, 2009) is consistent with the
predisposition to lymphoid tumour development that involves
chromosome translocations, derived through errors in immune
system gene rearrangement, occurring in A-T patients often at an
earlier age than the same tumour in the normal population (Taylor
et al, 1996).
In contrast, heterozygous female ATM mutation carriers in A-T
families have an increased risk of developing breast cancer,
without any evidence for an increased risk of lymphoid tumours
(Swift et al, 1991; Geoffroy-Perez et al, 2001; Olsen et al, 2001;
Thompson et al, 2005). Ataxia-telangiectasia shows substantial
phenotypic heterogeneity, both neurological (Hiel et al, 2006;
Verhagen et al, 2009) and immunological (Staples et al, 2008).
There is also substantial allelic heterogeneity, and a consideration
of possible mechanisms for tumour development in A-T patients
must take into account the expression of either different mutant
ATM proteins, or combinations of two ATM proteins with or
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swithout kinase activity. We sought to establish the relationship
between absence or presence of ATM kinase activity and cancer
risk, based on a large cohort of A-T patients from the UK and the
Netherlands.
MATERIALS AND METHODS
Patient cohort
Ethical approval was given by the National Research Ethics
Committee (REC reference 07/H1210/155). Ataxia-telangiectasia
patients from the UK (n¼244) and the Netherlands (n¼52) were
included in the analysis (Table 1). Participants were recruited on
the basis of a clinical diagnosis of A-T and without reference
to their cancer status. The follow-up period was defined as
beginning at birth and continuing until the earliest of death, cancer
diagnosis, loss of contact or database completion. Time period
of follow-up ranged from 10 months to 66 years (median¼
18 years, IQR¼11–28 years), with a total of 6239 person-years of
follow-up.
Identification of A-T patients whose cells expressed ATM
kinase activity
As many as possible ATM mutations were identified mainly by
genomic sequencing (primer data available on request), in all UK
and Dutch A-T patients, both with tumours (ATM mutations
categorised in Supplementary Tables S1–S5) and without tumours
(mutations not shown). Cell lines were available from all UK
A-T patients and most Dutch A-T patients. In conjunction with
sequencing, we also used western blotting on all cell lines to
determine whether or not there was expression of ATM protein. As
our hypothesis was that expression of residual ATM kinase
protected against tumour development in A-T patients, we also
determined whether cells showed ATM kinase activity as assessed
by detection of phosphorylated substrates of ATM, using phospho-
specific antibodies (see Materials And Methods below). Using a
combination of ATM mutation identification and western blotting
for ATM protein detection, the following were used as criteria by
which cells were deemed not to have any ATM kinase activity.
Criteria by which cells were deemed not to have any ATM kinase
activity
(1) The presence of two truncating ATM mutations. Truncating
ATM mutations result in instability and loss of the ATM
protein from the cell. Therefore, those A-T patients with two
truncating ATM mutations were assumed not to express ATM
protein (and therefore no ATM kinase activity). Nevertheless,
western blotting was used to confirm, in most cases, whether
or not cell lines expressed any ATM protein. We could show
that where there were two truncating ATM mutations there
was always absence of ATM protein (Supplementary Table S1).
(2) Where ATM was found to be expressed, the mutational cause
was always investigated. Where ATM protein was expressed,
ATM kinase activity was measured. Absence of ATM kinase
activity was associated with following types of mutation
producing ATM protein (Supplementary Table S2, Supple-
mentary Figure S1).
(i) Some founder mutations (e.g., c.7638_7646del9; p.Arg2547_
Ser2549del) resulted in loss of three in-frame amino acids
(Stankovic et al, 1998); previous work showed expression of a
low level of mutant protein and absence of ATM kinase
activity (Stewart et al, 2001).
(ii) Splice site mutations, resulting in exon skipping, that allowed
expression of a very low level of ATM protein, were tested for
ATM kinase activity. In all the cases, measurable kinase
activity was absent. These occurred, for example, in 25 out of
66 A-T patients with tumours (Supplementary Table S2).
(iii) A small group of A-T patients carried missense mutations
that did not result in expression of any ATM protein (for A-T
patients with tumours, see Supplementary Table S1).
(iv) A small group of A-T patients carried missense mutations
that resulted in expression of low-level mutant protein but
without any activity (for A-T patients with tumours, see
Supplementary Table S2).
(v) Mutation in the initiating methionine of the coding sequence
leading to likely use of the next downstream methionine, as
judged by the slightly truncated mutant protein (for A-T
patients with tumours, see Supplementary Table S2).
(vi) A small group of A-T patients carried mutations that resulted
in expression of an almost normal level of mutant ATM
protein but without any kinase activity. In the non-tumour
patients, these included c.9022C4T (p.Arg3008Cys) (Angele
et al, 2003) and in 3 out of 66 tumour patients, two with
c.8293G4A (p.Gly2765Ser) (Supplementary Table S3,
Supplementary Figure S2).
In total, 135 out of 185 A-T patients without tumours showed
absence of ATM kinase activity and out of 66 patients with
tumours 51 did not show kinase activity.
Criteria by which cells were deemed to have ATM kinase
activity With respect to the presence of ATM kinase activity,
this was always observed in cells from A-T patients with or without
tumours who carried:
(i) The c.5763-1050A4G (p.Pro1922fs) leaky splice site muta-
tion (all from the UK and Ireland). Where not tested, cells
with this mutation were assumed to be expressing a low level
of normal ATM with kinase activity as previously shown
(McConville et al, 1996; Stewart et al, 2001), (Supplementary
Table S4, Supplementary Figure S4).
(ii) The c.1066-6T4G p.Val356fs mutation. This is assumed to be
a leaky splice site mutation (Austen et al, 2008) (Supple-
mentary Table S4, Supplementary Figure S4).
(iii) Some, but not all, missense mutations. These could express
either a relatively high level of mutant ATM protein (e.g.,
c.7271T4G; p.Val2424Gly) (Stankovic et al, 1998; Stewart
et al, 2001) or a low level (c.8494C4T) mutant ATM
protein (Barone et al, 2009), but with clear ATM kinase
activity (Supplementary Table S4, Supplementary Figure S4);
therefore, the mutant ATM could have either low (e.g.,
p.Val2424Gly) or high (e.g., p.Arg2832Cys) specific activity.
Table 1 Details of the study cohorts
Cohort
No. of A-T patients
(male/female)
No. of
families
No. of
cancers
No. of
person-years
Median age at end
of follow-up
a (IQR)
ATM kinase activity
present/absent/unknown
UK 244 (130/114) 208 47 5044 18 (11-28) 52/151/41
The Netherlands 52 (25/27) 38 19 1195 16.5 (11–34) 12/36/4
All 296 (155/141) 246 66 6239 18 (11–28) 64/187/45
Abbreviations: A-T¼ataxia telangiectasia; ATM¼ataxia telangiectasia mutated; IQR¼inter-quartile range; UK¼United Kingdom.
aFollow-up period began at birth and
continued until the earliest of death, first cancer diagnosis, loss of contact or database completion.
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presence of some ATM kinase activity and 14 out of 66 A-T
patients with tumours (in one tumour patient the ATM kinase
activity could not be determined – Supplementary Table S5). The
ATM kinase activity in these individuals, therefore, came either
from normal ATM as a result of a leaky splice site mutation or
from mutant ATM expressed by an allele with a missense
mutation.
The smaller proportion of tumours in UK compared with Dutch
A-T patients was due in part to the presence of the IVS40 splice site
mutation in the British and Irish population and also the higher
proportion of older Dutch patients with more years at risk.
Cell culture
We derived a lymphoblastoid cell line from each A-T patient’s
blood by separating the lymphocytes, infecting the peripheral
blood mononuclear cells with Epstein–Barr virus by adsorption
for 4h, followed by addition of cyclosporin A (0.1mgml
 1) to kill
any remaining T cells and allowing 14 days for the transformed
B lymphocytes to emerge. The lymphoblastoid cell line was subse-
quently grown in RPMI 1640 medium (Sigma-Aldrich, Irvine, UK)
supplemented with 10% fetal calf serum (PAA Laboratories,
Pasching, Austria). We derived lymphblastoid cell lines from
normal controls in the same manner.
Immunoblotting for ATM expression and ATM activity
assays
For ATM protein expression assays, patient-derived lymphoblas-
toid cells were harvested and cell pellets were resuspended in UTB
buffer (9 M urea, 50mM Tris, pH 7.5, 150mM b-mercaptoethanol)
and lysed on ice by sonication. For ATM activity assays, patient-
derived lymphoblastoid cells were either mock-irradiated or
exposed to 5Gy ionising radiation and harvested after 30min
before the cell pellets were resuspended in UTB buffer and lysed
on ice by sonication. Whole-cell lysate (50mg) was separated by
SDS–polyacrylamide gel electrophoresis, and the proteins trans-
ferred to nitrocellulose membrane (Pierce, Rockford, IL, USA).
Nitrocellulose strips were subjected to immunoblotting and the
protein bands visualised using the enhanced chemiluminescence
(ECL) system (Amersham, Little Chalfont, UK) and exposing to
Hyperfilm MP autoradiography film (GE Healthcare, Little
Chalfont, UK). Antibodies used for immunoblotting were ATM
(custom-made mouse monoclonal antibody clone 11G12 pre-
viously described), pATM Ser1981 #AF1655 (R&D Systems,
Abingdon, UK), Smc1 #A300-055A, pSmc1 Ser966 #A300-050A,
Nbs1 #Ab398, pNbs1 Ser343 #Ab47272 (Abcam, Cambridge, UK),
p53 Ser15 #9284, pChk2 Thr68 #2661, Chk2 and p53 (gift from
Dr G Stewart).
Statistical methods
The statistical analyses were based on data from 296 A-T patients
from the UK (n¼244) and the Netherlands (n¼52), having
excluded 13 A-T patients for whom date of birth was unknown.
For the main analysis, the at-risk person-years were defined as
beginning at birth and continuing until the earliest of death, first
cancer diagnosis, loss of contact or database completion (end of
2009 for the Netherlands; March 2010 for UK). Cancer incidence
rate ratios for patients with ATM kinase activity relative to a
baseline of no kinase activity were estimated using Poisson
regression. Survival until cancer diagnosis for patients with and
without kinase activity was compared using a Kaplan–Meier plot
and the log-rank test. Differences in the proportions of lymphoid
and non-lymphoid tumours between age-groups and between
kinase-absent and -present patients were compared using Fisher’s
exact test. We were not able to obtain kinase activity information
from all patients, but this did not introduce bias, as all compa-
risons were between patients with known status.
The breast-cancer-specific analysis, differed in that follow-up,
continued until the earliest of breast cancer diagnosis, death, loss
of contact or database completion, and was left-truncated at 1960,
as population rates are unreliable before this date.
RESULTS
Distribution of tumours in the patient cohort
Overall, 66 first cancer diagnoses were made including several rare
types of tumour; 47 tumours were lymphoid and 19 non-lymphoid;
42 were diagnosed p16 years of age and 24 were diagnosed 416
years (Table 2). The proportion of tumours, which were lymphoid,
was significantly greater in the younger age-group (P¼0.002).
Of the 44 families with multiple cases of A-T, 7 families
contained two A-T patients with a cancer diagnosis. For five of
the families, the two cases were of the same tumour type (breast
cancer, mixed-cellularity Hodgkin’s lymphoma, Hodgkin’s lym-
phoma, T-cell lymphoma and T-ALL, respectively). The other two
families contained a T-PLL and a pancreatic cancer, and a
myeloma and a myeloid leukaemia, respectively.
Relationship of the presence of ATM kinase to tumour
Our hypothesis was that the majority of tumours at p16 years
were related to absence of ATM kinase activity. We sought to
identify the ATM mutations in as many patients as possible, and
to determine whether their cells expressed any ATM protein with
residual ATM kinase activity (Supplementary Tables S1–S5 and
Supplementary Figures S1–S4). We were able to determine
whether there was any ATM kinase activity for 251 patients; 187
showed no kinase activity and 64 did. Overall survival until first
cancer diagnosis was significantly better among A-T patients with
some ATM kinase activity (log-rank test P¼0.0001) (Figure 1).
The proportion of tumours that were lymphoid as opposed to non-
lymphoid was significantly lower in those with some ATM kinase
activity (P¼0.018) (Table 2).
Table 3 shows the incidence rates of lymphoid and non-
lymphoid tumours, according to the absence or presence of
ATM kinase activity. The incidence rate for lymphoid tumours
was significantly lower in those with kinase activity than in those
without (incidence rate ratio (IRR)¼0.22, 95% confidence interval
(CI)¼0.10–0.49, Po0.001), but there was no difference in the
rates of non-lymphoid tumours between the two groups (P¼0.91).
The presence of kinase activity was also associated with a lower
risk of lymphoid tumours when restricted to tumours diagnosed
p16 years of age (IRR¼0.15, 95% CI¼0.03–0.63, P¼0.01 for
lymphoid tumours) (Table 4). All six of the non-lymphoid
tumours diagnosed at p16 years, including three brain tumours,
were in patients with no kinase activity, hence it was not possible
to estimate a non-lymphoid IRR. In fact, only two cancers of any
type were diagnosed before the age of 16 years in A-T patients with
kinase activity; a T-cell lymphoma at an age of 2 years in a patient
with two missense mutations and T-ALL at 9 years in a patient
with both a frameshift and leaky splice site mutation (Supple-
mentary Table S4).
The IRRs associated with kinase activity were less extreme in the
over-16 age-group, and none of the differences were significant,
possibly due to the smaller numbers of tumours. Importantly, the
proportion of A-T patients with kinase activity was significantly
higher in the older age-group; of patients with known kinase
status, 64 out of 251¼25% of patients in the p16 age-group had
kinase activity, compared with 57 out of 138¼41% of patients who
survived beyond the age of 16 years (P¼0.002). This likely reflects
ATM kinase activity and tumour risk in A-T
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active mutations, as well as the lower cancer risk.
In the 24 A-T adults with a tumour, 11 were of lymphoid origin,
7 with the same spectrum as the paediatric lymphoid tumours
(Table 2). The remaining five included four T-PLLs (diagnosed at
ages 27, 32, 35 and 43 years) and a myeloma (48 years), all
normally associated with old age in the general population. The 13
non-lymphoid adult tumours consisted of one pancreatic, two
thyroid, one ectopic pituitary, a testicular seminoma, a myeloid
tumour and seven breast cancers (Table 2). The breast cancers
were diagnosed at ages 27, 32, 37, 43, 44, 44 and 50 years and were
all diagnosed in women.
Given the existing evidence for an increased risk of breast cancer
in female heterozygous ATM mutation carriers (Swift et al, 1991;
Olsen et al, 2001; Thompson et al, 2005; Geoffroy-Perez et al,
2001; Renwick et al, 2006), we performed a separate analysis of
breast cancer risk in A-T patients (i.e., with biallelic ATM
mutations) Using breast cancer diagnosis as the exit criteria,
rather than diagnosis with any cancer, the cohort contained an
eighth eligible breast cancer, diagnosed at the age of 29 years
following a T-ALL at the age of 15 years. Overall, 0.26 breast
cancers were expected in these 141 women (2963 person years)
according to population rates (UK and the Netherlands, as
appropriate, by 5-year age-group and B5-year calendar period)
(see Supplementary references for cancer in five continents). This
gives a standardised mortality ratio of 31.1 (with a wide 95%
CI¼14.4–74.7) equivalent to a cumulative risk of breast cancer
diagnosis by the age of 50 years of 45% (95% CI¼24–76%), or
10-year risks of 13% (95% CI¼6–28%) between ages 30–39 years
and 36% (95% CI¼19–66%) between ages 40–49 years.
DISCUSSION
We show here that development of childhood tumours (lymphoid
and brain) in A-T patients is associated almost exclusively with
absence of ATM kinase activity. Conversely our findings suggest
that expression of some residual ATM kinase activity has a
strongly protective effect against tumour development in A-T in
childhood. The source of the residual ATM kinase activity was a
low level of either normal ATM or mutant ATM. The origin of the
retained kinase activity in 25 patients (median age, 29 years) was
the presence of the IVS40-1050A4G splice site mutation
(McConville et al, 1996; Stewart et al, 2001; Sutton et al, 2004)
expressing a low level (B5%) of normal ATM. Despite the
protection against tumour development provided by retained ATM
kinase activity, two developed tumours, although significantly only
in adulthood (one patient had a T-ALL at 17 years of age; the other
patient had a testicular seminoma at an age of 27 years and a
cerebral diffuse large B-cell lymphoma at an age of 34 years). This
apparent contradiction may be reconciled if the level of ATM
kinase activity in these IVS40-1050A4G-carrying patients is close
to a threshold of ATM kinase activity that would normally be
tumour suppressive.
Ataxia telangiectasia patients also clearly show a very substan-
tially increased risk of breast cancer at young ages; the estimated
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Figure 1 Kaplan–Meier survival to cancer diagnosis by ATM kinase
activity. Shaded areas are 95% CIs. The solid line is for A-T patients with no
ATM kinase activity, and the dashed line is for patients with some kinase
activity. The values under the graph refer to the number of patients in each
group at risk at the corresponding analysis time.
Table 2 Tumour types observed in ataxia telangiectasia patients by age
and presence/absence of ATM kinase activity
Lymphoid tumours n Non-lymphoid tumours n
Diagnosed p16years
ATM kinase absent 33 6
AILD
ALL
B cell lymphoma (5)
B cell NHL (2)
Burkitt-like lymphoma
Hodgkin’s lymphoma (3)
Hodgkin’s-mixed cellularity
Hodgkin’s lymphoma, T-ALL
Lymphoma (6)
Lymphosarcoma
NHL
T cell lymphoma (3)
T-ALL (7)
Astrocytoma
DFSP
Ganglioglioma
Hepatocellular carcinoma
Medulloblastoma
Myeloid leukaemia
ATM kinase present 2 0
T cell lymphoma
T-ALL
ATM kinase unknown 1 0
B cell NHL
Diagnosed 416years
ATM kinase absent 7 4
B cell lymphoma
Burkitt lymphoma
Hodgkin-mixed cellularity
T-ALL
T-PLL (3)
Breast cancer (2)
Pancreatic cancer
Testicular seminoma
ATM kinase present 4 9
ALL
Myeloma
T-ALL
T-PLL
Breast cancer (5)
Ectopic pituitary tumour
Myeloid leukaemia
Thyroid carcinoma (2)
Abbreviations: AILD¼angioimmunoblastic T-cell lymphoma; ALL¼acute lympho-
blastic leukaemia; ATM¼ataxia telangiectasia mutated; DFSP¼dermatofibro-
sarcoma protuberans; NHL¼non-Hodgkin’s lymphoma; T-ALL¼T-cell acute
lymphoblastic leukaemia; T-PLL¼T-cell-prolymphocytic leukaemia. Numbers in
brackets indicate number of cases when this is 41. In addition, the patient with a
testicular seminoma at an age of 27 years went on to develop a cerebral diffuse large
B-cell lymphoma (DLBL) at an age of 34 years. One of the patients with a T-ALL at
age of 15 years (kinase absent) also went on to develop a breast cancer at an age of
29 years. Of the 44 families with multiple cases of A-T, 7 families contained two A-T
patients with a cancer diagnosis. For five of the families, the two cases were of the
same tumour type (breast cancer, mixed-cellularity Hodgkin’s lymphoma, Hodgkin’s
lymphoma, T-cell lymphoma and T-ALL, respectively). The other two families
contained a T-PLL and a pancreatic cancer, and a myeloma and a myeloid leukaemia,
respectively.
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equivalent risks, in unselected carriers of BRCA1 or BRCA2
mutations (31% and 20%, respectively) (Antoniou et al, 2008). In
contrast, the breast cancer risk, by the age of 50 years, associated
with a heterozygous ATM mutation, is B9% (Thompson et al,
2005). Given the small number of adult female A-T patients, the
95% CI for this estimate is wide (24–76%), but even the lower
bound would represent a very important level of risk. The eight
cases included a pair of sisters who are homozygous for the
c.7271T4G (p.Val2424Gly) mutation, and who have previously
been reported as having breast cancer (Stankovic et al, 1998). This
mutation has also been reported as being a breast cancer risk allele
in its heterozygous form (Chenevix-Trench et al, 2002). Excluding
these two sisters (the only 7271T4G carriers in this study), the
estimated breast cancer risk by the age of 50 years was 39% (95%
CI¼18–75%), hence, the high risk among A-T patients is not
restricted to this mutation. This observation has important
implications for the clinical management of women with AT.
Two unrelated breast cancer A-T patients were compound
heterozygous for the p.Val2716Ala protein, which retains some
ATM kinase activity, although greatly reduced compared with
normal (Verhagen et al, 2009). Interestingly, development of breast
cancer, in A-T patients, may occur either in the total absence of
ATM kinase activity (Supplementary Tables S1–S3) or in the
presence of a low level of retained ATM activity (Supplementary
Table S4), and it is the longer survival of A-T patients with some
residual ATM kinase that allows this predisposition for breast
cancer to manifest.
Overall, the protective effect of residual ATM kinase does not
appear to extend to non-lymphoid tumours. The difference may be
because the mechanism for development of these solid tumours is
different to the translocation-driven lymphoid tumour.
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kinase absent patients (95% CI)
Age-group
ATM kinase
status
Person-
years Cancers
Lymphoid/
non-lymphoid All cancer Lymphoid
Non-
lymphoid
All
cancer Lymphoid
Non
-lymphoid
p16 years Kinase absent 2398 39 33/6 16.3 (11.6–22.2) 13.8 (9.5–19.3) 2.5 (0.9–5.4)
Kinase present 990 2 2/0 2.0 (0.2–7.3) 2.0 (0.2–7.3) n/a 0.12 (0.03–0.53)
P¼0.005
0.15 (0.03–0.63)
P¼0.01
n/a
Kinase unknown 595 1 1/0 1.7 (0–9.4) 1.7 (0–9.4) n/a
Total 3983 42 36/6 10.5 (7.6–14.3) 9.0 (6.3–12.5) 1.5 (0.6–3.3)
416 years Kinase absent 860 12 7/5 14.0 (7.2–24.4) 8.1 (3.3–16.8) 5.8 (1.9–13.6)
Kinase present 1175 12 4/8 10.2 (5.3–17.8) 3.4 (0.9–8.7) 6.8 (2.9–13.4) 0.68 (0.32–1.47)
P¼0.33
0.41 (0.12–1.34)
P¼0.14
1.05 (0.36–3.09)
P¼0.93
Kinase unknown 221 0 0/0 n/a n/a n/a
Total 2256 24 11/13 10.6 (6.8–15.8) 4.9 (2.4–8.7) 5.8 (3.1–9.9)
Abbreviations: ATM¼ataxia telangiectasia mutated; CI¼confidence interval. Incidence rate ratios are adjusted for country of residence.
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